Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autogenous Partially Demineralized Dentine Matrix (APDDM) is a biological bone graft material derived from a patient's own extracted teeth, specifically processed for use in alveolar ridge preservation and bone augmentation. The preparation involves cleaning the extracted tooth, removing all restorative materials, and milling the dentin into particles. These particles are then partially demineralized using a solution of hydrochloric acid and hydrogen peroxide, a process that preserves the organic matrix while exposing essential growth factors. APDDM contains Type I collagen and various signaling molecules, including Bone Morphogenetic Proteins (BMPs) and Transforming Growth Factor-beta (TGF-β), which provide both osteoconductive and osteoinductive properties. This autogenous approach minimizes the risk of immunological rejection and disease transmission while promoting rapid and high-quality new bone formation. Cairo University has been a key institution in evaluating its clinical efficacy compared to allogeneic alternatives in the aesthetic zone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Autogenous Partially Demineralized Dentine Matrix.